leisure time -WSS

leisure time

author：explore 2025-10-02 19:55:19 - browse：9151

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Argenx drug significantly slows progression of nerve disorder

entertainment

leisure time

WSS

Thousands protest in Iraq for a second day over burning of Quran in Sweden

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Involuntary treatment for addiction doesn't work

Georgia court denies Trump's request to quash DA's 2020 election probe

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Medical experts exlpore how to eliminate bias in clinical algorithms

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Congress likely to miss an opportunity to fix drug shortages issue

Novavax promises a turnaround & Lilly roils the obesity market

Global childhood vaccinations edge closer to pre

How to save PrEP access — and even expand it

Tuskegee Airman Raymond Cassagnol dies at 102

Malaria cases in Florida and Texas: Here’s what you need to know

Does aspartame cause cancer? What new WHO guidance says

Jerome Adams on the need for new antivirals for Covid

Grail faces three suits alleging harassment, retaliation

focus

Everything to know for the next Powerball drawing as jackpot hits $1 billion

GOP inquiry over gain

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Eating disorder hotline's move to chatbot carried cost for volunteers

Eli Lilly to acquire Versanis in heated race for weight loss drugs

J&J expands global access to TB drug amid advocacy campaign

entertainment

leisure time

leisure time

hotspot